Key statistics
On Friday, Immunitybio Inc (IBRX:NSQ) closed at 3.52, 181.60% above the 52 week low of 1.25 set on Oct 19, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.48 |
---|---|
High | 3.55 |
Low | 3.39 |
Bid | 3.52 |
Offer | 3.63 |
Previous close | 3.48 |
Average volume | 2.93m |
---|---|
Shares outstanding | 696.53m |
Free float | 159.61m |
P/E (TTM) | -- |
Market cap | 2.45bn USD |
EPS (TTM) | -0.9356 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
- ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
- ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer